5 Key Takeaways

• 1

  Continuation of GLP-1 receptor agonists in the first trimester does not show a clear increase in nonlive birth or major congenital malformations.

• 2

  The study analyzed 3,572 pregnancies, comparing outcomes between those who continued GLP-1 treatment and those who did not.

• 3

  The adjusted risk ratio for nonlive birth was 1.09, indicating no significant difference in risk between treatment groups.

• 4

  Elective termination rates were higher among patients who continued GLP-1 treatment, potentially due to various influencing factors.

• 5

  The study's observational design has limitations, including potential residual confounding and imprecise estimates for some outcomes.